<DOC>
	<DOCNO>NCT03012763</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics probe-drugs sulfasalazine , give 240 ml non-caloric water paracetamol , fexofenadine valsartan oral administration , give 240 ml non-caloric water , 240 ml caloric drink 240 ml grapefruit juice prior ingestion visualize localization measure fill volume stomach , small intestine well ascend , transverse descend colon T2-weighted magnetic resonance image oral administration 240 ml water ( non-caloric water ) , administration 240 ml caloric drink administration 240 ml grapefruit juice .</brief_summary>
	<brief_title>Oral Pharmacokinetics Sulfasalazine , Paracetamol , Fexofenadine Valsartan Using Different Administration Mediums</brief_title>
	<detailed_description />
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>ethnic origin : Caucasian body mass index : ≥ 18.5 kg/m² ≤ 30 kg/m² good health evidence result clinical examination , ECG , laboratory checkup , judge clinical investigator differ clinical relevant way normal state write informed consent weight less 45 kg claustrophobia tinnitus cardiac pacemaker , metallic , plastic silicone implant , dental retainer metalcontaining tattoos piercings , Permanent MakeUps , intrauterine device know allergic reactions/ hypersensitivity active ingredient use constituent study medication ( e.g . lactose , lecithin , sulfonamide , salicylate ) bronchial asthma ( stage ) know allergic disease exist cardiac , haematopoietic hematological disease and/or pathological finding , might interfere drug 's safety , tolerability and/or pharmacokinetics requirement magnetic resonance tomography know hyperkalemia , hyponatremia hypovolemia medication may cause condition . Hepatic , renal metabolic disease and/or pathological finding , might interfere pharmacokinetics pharmacodynamics study medication ( e.g . liver failure , kidney failure , acute intermittent porphyria ) . gastrointestinal disease and/or pathological finding , might interfere gastrointestinal motility empty process interfere pharmacokinetics pharmacodynamics study medication ( e.g . ileus ) Erythema exsudativum multiforme . Glucose6phosphate dehydrogenase deficiency ( G6PD deficiency ) . Acute , chronic recurrent infection . drug alcohol dependence positive drug alcohol screen smoker 10 cigarette per day positive result HIV , hepatitis B virus hepatitis C virus screening subject diet could affect gastrointestinal motility pharmacokinetics drug ( vegetarian , vegan ) eat disorder e.g . anorexia , bulimia heavy tea coffee drinker ( 1l per day ) lactation and/or pregnancy test positive perform subject suspect know follow instruction subject unable understand write verbal instruction , particular regard risk inconvenience expose result participation study subject liable orthostatic dysregulation , faint blackout participation clinical trial last 3 month prior plan start study le 3 month last blood donation therapy transdermal patch systemically available medication within 2 week prior intend first administration unless terminal elimination halflife complete elimination body assume drug and/or primary metabolite ( except oral contraceptive ) intake grapefruit poppy seed contain product within 14 day prior start study Females n't fulfil criterion contraception list section 7.5.1 protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>